Effectiveness of Antiretroviral Therapy in a Lower-Level Health Facility Setting in Uganda  by Kutamba, E. et al.
13th International Congress on Infectious Diseases Abstracts, Poster Presentations e203
25.009
Reduced Morbidity in the First Year After Initiating Highly
Active Antiretroviral Therapy Among Ugandan Adults
J. Mpendo, G. Miiro, C. Watera, P. Munderi, S. Nakubulwa,
I. Kaddu, D. Rutebarika ∗, J. Todd, H. Grosskurth
MRC/UVRI Uganda Research Unit, Entebbe, Uganda
Objective: To evaluate the effect of Highly Active Anti-
Retroviral Therapy (HAART) and cotrimoxazole prophylaxis
usage (CTX) on incidence of morbidity within the ﬁrst year
of HAART-eligibility.
Methods: Between July 1999 and April 2006, we collected
information on morbidity from an open cohort of HAART-
eligible patients (according to WHO criteria). We compared
morbidity among patients initiating HAART to morbidity
before the stepwise introduction of HAART and CTX. We used
available patients on HAART to select randomly a historical
group of HAART-na¨ıve but eligible patients who had propor-
tionally the same WHO stage and sex distribution. Patients
aged 16 years or older, visited the study team 6-monthly
and when ill. Patients’ demographics, WHO stage, HAART
status, CTX, any new morbidity event (disease, drug-related
and recurrent), haemoglobin and CD4 counts were collected
from the beginning of follow up to the ﬁrst year after initi-
ating HAART or becoming HAART-eligible. We estimated the
overall effect of HAART on morbidity; adjusted for the effect
of CTX by Mantel-Haenszel methods and adjusted for the
effect of other confounders by negative binomial regression.
Results: 219 HAART patients (median age 37 years;
73% women; 85% CTX; median Hb 11.7 g/dl and median
CD4 131 cells/ul) experienced 94 events. They contributed
127 Person-Years of Observations (PYOs). 616 HAART-na¨ıve
patients (median age 33 years; 70% women; 33% CTX; median
Hb 11.2 g/dl and median CD4 131 cells/ml) experienced 862
events. They contributed 474 PYOs. The overall morbidity
among HAART patients during their ﬁrst year of treatment
was 78% lower (HR = 0.22, 95% CI: 0.15—0.31) than the over-
all incidence among HAART-na¨ıve patients in unadjusted
analysis. CTX also had a protective effect against morbidity
(adjusted HR = 0.55, 95% CI: 0.38—0.79).
Conclusions: Morbidity reduced signiﬁcantly within the
ﬁrst year of initiating HAART in this setting. CTX had addi-
tional signiﬁcant protection against morbidity.
doi:10.1016/j.ijid.2008.05.503
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Clinical Signiﬁcance of Sub-Optimal CD4 Reconstitution
Despite Viral Suppression in An Urban Cohort Initiating
Antiretroviral Therapy in Sub-Saharan Africa
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Background: A proportion of individuals who start highly
active antiretroviral therapy (HAART) fail to achieve ade-
quate CD4 cell reconstitution. We determined the frequency
and clinical signiﬁcance of suboptimal CD4 reconstitution
despite viral suppression (SO-CD4) in an urban HIV clinic in
Uganda, where patients initiate HAART with severe immun-
odeﬁciency.
Methods: We analyzed data from a prospective research
cohort of 559 patients initiating HAART between 04/04-
04/05 at the Infectious Diseases Institute, Kampala. We
deﬁned SO-CD4 as either of a) <50 CD4 cells/l increase
after 6 months of HAART, b) <100 cells/l increase after 12
months and c) <200 cells/l after 24 months. We assessed
the cumulative risk of adverse clinical events [death and
recurrent or new acquired immunodeﬁciency syndrome
(AIDS)-deﬁning illness] by Kaplan-Meier analysis.
Results: Of 559 patients initiating HAART, 386 (69%) were
female, with a median age of 38 years (IQR 33—34), and
CD4 count of 98 cells/l (IQR 21-163); 283 (51%) had a CD4
count <100 cells. 414 (74%) started D4T + 3TC +NVP while145
(26%) started ZDV + 3TC + EFZ. After 6, 12 and 24 months of
HAART, 380 (68%), 339(61%) and 309 (55%) had attained and
sustained viral suppression; of these, 78 (21%), 151 (45%) and
166(54%) respectively had SO-CD4; and 165(43%), 143(42%)
and 57(19%) remained with CD4 count 200 cells/l and
remained at signiﬁcant risk of life-threatening oppotunistic
infections. Our results highlight the need for strategies to
encourage early HIV diagnosis and timely initiation of HAART.
doi:10.1016/j.ijid.2008.05.504
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Effectiveness of Antiretroviral Therapy in a Lower-Level
Health Facility Setting in Uganda
E. Kutamba ∗, F.S. Semitala, J.O. Ouma, S.M. Muhumuza,
D.M. Mwesigire, R.W. Wanyenze, M.K. Kamya
MJAP-Makerere University, Kampala, Uganda
Background: The burden of HIV care in Uganda is enor-
mous and continues to increase rapidly. Existing HIV care
clinics are congested with increasing numbers of patients
seeking care and treatment. There’s an urgent need to roll
out ART to lower level health centers and decongest the
more established HIV clinics. We evaluated the effective-
ness of Antiretroviral therapy (ART) among adult patients
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attending a peri-urban clinic supported by MJAP and funded
by PEPFAR.
Methods: From November 2005 to November 2007, con-
secutive treatment naive patients initiating ART at the clinic
were enrolled. Clinical information is collected every month
and CD4+ count measured every 6 months. This analysis
includes patients who had completed at least 10 months
of follow up. Response to therapy was assessed by changes
in CD4 cell counts, weight, and occurrence of opportunis-
tic infections. WHO staging, adherence levels and patient
retention were also assessed.
Results: During the study period, 694 of 2686 in care,
started ART; the mean age was 34 years, 76% were female,
40% were in WHO stage 3&4, mean body weight was 54.5 kg
(SD = 9.5) and median CD4 cell count 118/mm3.
Outcomes could not be assessed in 19% of 694 (43 died,
50 were lost to follow up, 36 were transferred out to other
health centers).
The mean increase in CD4+ count at 6 months was
135/mm3 and median body weight increase was 5.0 kg. 68%
of 565 active gained weight. ART initiation reduced inci-
dence of opportunistic infections(OR:3.35, P = 0.003;). Over
98% of patients had >95% adherence. Patients with WHO
stage 1&2 were twice more likely to be active compared
to those with WHO stage 3&4.(OR:1.84, P = 0.002).
Conclusion: HAART programs can be feasibly imple-
mented at lower health facilities providing general
outpatient care with satisfactory clinical and immunological
outcomes and patient retention rates.
doi:10.1016/j.ijid.2008.05.505
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An Advanced ARV Drug Resistance Expert Rule System in
BioNumerics®
K. Janssens ∗, B. Pot, D. Michielsen, L. Vauterin, P. Vauterin
Applied Maths NV, Sint-Martens-Latem, Belgium
Automated drug resistance predictions, based on muta-
tion analysis, is increasingly important in virology. Unfortu-
nately most mutation analysis systems are closed systems,
leaving the user unaware on which mutation rules are ﬁred
and what part of data caused them to ﬁre. Based on curves
obtained after direct sequencing, mutants can easily be
spotted, identiﬁed and inventoried.
We present an integrated open Expert Rule System (ERS)
build into the BioNumerics® software that allows researchers
to create, adapt and (re)evaluate e.g. drug resistance rules
(double loop learning). The ERS consists of 5 major steps:
- data input directly from the BioNumerics® database or
from external sources (e.g. RT-sequences)
- data conversion for the data processing (e.g. AA-
conversion and mutation detection against a consensus)
- decision rules application, yielding a statistics report on
some or all rules (e.g. rules for all NRTI drugs)
- ERS interpretation, yielding resistance predictions for
each drug with anticipation scores based on fuzzy logic
- reporting in a written format, a database format, or pub-
lication on a website
The tool can be shown as an interactive GUI or run for
background HT batch analysis. The ERS was tested with pub-
licly available HIV data and drug resistance algorithms, but is
‘open’ for custom rule development. Discordances between
different algorithms can be easily monitored and examined.
This framework is not restricted to HIV, but can be used for
e.g. HBV as well.
doi:10.1016/j.ijid.2008.05.506
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Identifying Trends in Viral Replication and Immune Status
Markers Among Patients Living with HIV: Impact of the
Initial Antiretroviral Therapeutic Regimen on Response to
Treatment
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Brazil
2 Institute of Mathematics and Statistics, University of Sao
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In HIV infection, a long asymptomatic period precedes
disease development. However, viral-host interaction is
dynamic. Mathematical models have been crucial to rule
out the concept of viral latency. The present study aims
at evaluating viral-host interactions in HIV infection, inves-
tigating the impact of initial antiretroviral therapy (ART)
(mono therapy vs. double therapy vs. highly active ther-
apy) in the course of disease. Using a database with at
least six sequential CD4+ cell counts and HIV viral load
assessments of 1391 patients under follow-up in Sa˜o Paulo,
Brazil, we classiﬁed patients according to a linear approx-
imation model of plasma viral loads and CD4+ cell counts
into favourable and unfavourable outcomes. We validated
the linear approach according to two criteria, based on 2
and Q 2 (
2/degrees of freedom). Association between out-
comes and the initial therapy was sought after analyzing
the viral load and CD4+ cell counts slopes. No particu-
lar initial regimen was shown associated with plasma viral
undetectability during follow-up. Only 20% of patients with
persistent vireamia presented a beneﬁcial effect of ART.
Unfavourable outcomes were associated with most patients
who resumed vireamia transiently or at the end of follow-
up. For most patients with intermittent vireamia ending
with undetectable or detectable viral loads, results indi-
cated favourable and unfavourable outcomes, respectively,
regardless of the initial ART regimen. Distinct outcomes
occurred among patients with oscillatory viral loads: most
of those who started therapy with two or three drugs
had a favourable outcome, in contrast to those started on
monotherapy. We conclude that mathematical tools have
demonstrated that the initially prescribed ART was not asso-
ciated with the long-term response to therapy for most
analysed patients. Favourable outcomes can be associated
to reinforcement of adherence or changes in ART regimens
during follow-up. Emergence and positive selection of drug-
resistant viral strains might be hypothesized as implicated
in unfavourable outcomes.
doi:10.1016/j.ijid.2008.05.507
